The rise of transplant oncology in primary liver cancer and metastatic disease
Transplant oncology reshapes the therapeutic landscape of liver malignancies, with growing evidence supporting liver transplantation in carefully selected patients beyond traditional indications. Optimized downstaging, innovative donor strategies, and tailored immunosuppression are pivotal for safe expansion. Continued collaboration between the transplant and oncology disciplines, along with prospective trials, is essential to further define standardized protocols and solidify transplantation as a cornerstone of multidisciplinary cancer care.
Authors
- Anudari Zorigtbaatar (ORCID: https://orcid.org/0000-0002-5050-8967)
- TM Wong
- Parissa Tabrizian (ORCID: https://orcid.org/0000-0002-7881-7497)
- Christian Toso (ORCID: https://orcid.org/0000-0003-1652-4522)
- Albert Chi Yan Chan
- Laia Aceituno Sierra
- Zhihao Li
- Pål Dag Line
- G. Sapisochin
- Julie Heimbach
- Vincenzo Mazzaferro
- René Adam
- Arndt Vogel
- Rebecca Marino
Institutions
- University of Geneva (CH)
- Oslo University Hospital (NO)
- Mount Sinai Hospital (US)
- Mayo Clinic (US)
- University of Oslo (NO)
- University of Toronto (CA)
- Université Paris-Saclay (FR)
- Queen Mary Hospital (CN)
- Institut Gustave Roussy (FR)
- Princess Margaret Cancer Centre (CA)
- Medizinische Hochschule Hannover (DE)
- Mount Sinai Medical Center (US)
- Assistance Publique – Hôpitaux de Paris (FR)
- Vall d'Hebron Hospital Universitari (ES)
- Fondazione IRCCS Istituto Nazionale dei Tumori (IT)
- Hôpital Paul-Brousse (FR)
- University of Hong Kong (HK)
Publication Details
- Journal
- Hepatology
- Published
- 2026-02-25
- DOI
- https://doi.org/10.1097/hep.0000000000001723
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00